Paul L. Berns
Independent DirectorMr. Paul L. Berns is Director of RhyGaze AG. He is a Co-Founder and Executive Chairman of the Board of Ollin Biosciences Inc. He serves as a Director at Kardigan, Inc since June 2024. He has been Executive Chairman of Neumora Therapeutics, Inc. since August 14, 2026. He previously served as CEO of Neumora Therapeutics, Inc. from February 14, 2025 until August 14, 2026. Mr. Berns was Independent Director of Metsera, Inc. from May 2023 until November 13, 2025. He Co-Founded at Metsera, Inc. and was its Lead Independent Director until November 13, 2025. Mr. Paul serves as Director at Mirador Therapeutics. He serves as Chairman of the Board at Human Immunology Biosciences, Inc. He serves as Chairman at Human Immunology Biosciences (HI-Bio). He had been a Director of Elephas Biosciences Corporation since September 06, 2022 until 2025. He serves as a Director of Areteia Therapeutics. He Co-Founded of Neumora Therapeutics, Inc and serves as its Chairman of the Board since January 2020 until July 2023. He served as CEO of Neumora Therapeutics, Inc. until July 2023. Mr. Berns was Executive Chairman of the Board at Neumora Therapeutics, Inc. since January 2020 until 2023 and served as its Director since January 2020 until 2023. Mr. Berns is a Co-Founder and Chairman at Happy Health, Inc. He is a Board Member of Human Immunology Biosciences (HI-Bio) since March 2021. He serves in the board of directors of Elephas Biosciences Corporation. Mr. Berns served as Chairman of the Board at Epirium Bio, Inc. (Cardero Therapeutics, Inc.) and serves as its Director since July 2019. He has deep business expertise across venture capital, biopharmaceuticals and biotechnology. He served as Lead Independent Director of Unity Biotechnology, Inc. until April 04, 2025. Mr. Berns has been Executive Chairman of Blackthorn Therapeutics, Inc. since November 5, 2018. He served as an Independent Director of EQRx, Inc. (Former Name: CM Life Sciences III Inc.) since January 2020 until July 31, 2023. Prior to ARCH. Mr. Berns built and led three pharmaceutical companies that were acquired by some of the sector’s leading companies. He serves as a Managing Director at Arch Venture Partners, L.P since February 2021. Mr. Berns was a Venture Partner at Arch Venture Partners, L.P in 2018. He joined the Arch Venture Partner in 2018. He focuses on Biotechnology and Pharmaceuticals. He served as an Independent Director at Menlo Therapeutics Inc. since November 2017 until March 2020. Mr. Berns has been a consultant to the pharmaceutical industry since July 2016 until August 2018, as well as from August 2012 to March 2014. Mr. Berns served as the Chief Executive Officer and President of Anacor Pharmaceuticals, Inc. from March 2014 to June 24, 2016 and served as its Chairman from June 2013 to June 24, 2016. Mr. Berns served as the Chief Executive Officer and President of Allos Therapeutics Inc. from March 9, 2006 to September 2012. He was a self-employed consultant to the pharmaceutical industry from July 2005 to March 2006. He served as the President and Chief Executive Officer at Bone Care International Inc. from June 2002 to July 2005. He served as a Vice President and General Manager, Abbott Labs Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories from March 2001 to 2002; Vice President of Marketing at BASF Pharmaceuticals-Knoll from June 2000 to March 2001 and served in various positions of increasing responsibility at Bristol-Myers Squibb Company from March 1990 to June 2000 with last position held as Vice President, Neuroscience Marketing. Mr. Berns was a consultant to the pharmaceutical industry from July 2016 to August 2018, as well as from August 2012 to March 2014 and from July 2005 to March 2006. He served as Vice President of Marketing at Abbott Service AG. Mr. Berns vast industry experience as an executive in biotechnology and pharmaceutical companies. He served as the Chairman and Director of Cellectar Biosciences, Inc. from August 19, 2015 to June 29, 2016 and from November 7, 2013 to June 29, 2016 respectively. He also served as a member of the board of directors of Anacor Pharmaceuticals, Inc. from June 2012 to June 2016. He served as a Director of Azur Pharma Public Limited Company. He has been an Independent Director at Novelos Therapeutics, Inc since November 2013. He had been Director of Unity Biotechnology, Inc. since March 27, 2018 until April 04, 2025. Mr. Berns was a board member of MC2 Therapeutics from May 2017 to January 2020. He had been an Independent Director of Jazz Pharmaceuticals Public Limited Company since 2010 until July 29, 2021. Additionally, Mr. Berns is a board member of Areteia Therapeutics, Metsera Therapeutics, Elephas Biosciences, EnCarda, NICO Therapeutics, Ollin Biosciences and Unity Biotechnology (UBX). He serves as Director at Abbott Service AG. He serves as a Director of REN Pharmaceuticals, Inc. Mr. Berns previously served on the boards of Hi Bio, EQRx, Jazz Pharmaceuticals, PLC, MC2 Therapeutics, Menlo Therapeutics, Anacor Pharmaceuticals, XenoPort, Allos Therapeutics and Bone Care International. He served as an Independent Director at Xenoport, Inc. from November 28, 2005 to May 17, 2016. Mr. Berns served as a Director of Allos Therapeutics Inc. since March 9, 2006 to September 2012. He served as a Director of Jazz Pharmaceuticals, Plc since January 2012. He served as a Director of Bone Care International Inc. since June 2002 until July 2005. Mr. Berns received a B.S. in Economics from the University of Wisconsin.
Positions
- Company NameKardigan, Inc.Stock CodeKARDPositionIndependent DirectorColleagues
- TATassos Anastasios E. GianakakosCo-Founder, President, CEO & Chairman
- JEJay EdelbergCo-founder & Chief Medical Officer
- BPBrianne PuglisiChief Financial Officer
- BMBob McDowellCo-founder & Scientific Advisor
- LALeslie A. LeinwandCo-Founder
- KJKimberly Johnston PopovitsIndependent Director
- DPDavid P. MeekerIndependent Director
- KRKristin ReinkeIndependent Director
- PLPaul L. BernsIndependent Director
- Company NameNeumora Therapeutics, Inc.Stock CodeNMRAPositionExecutive ChairmanColleagues
- JPJoshua PintoPresident, CEO & Director
- DSDaljit Singh AuroraChief Operationg & Development officer
- MLMichael Lee MilliganCFO & Principal Accounting Officer
- NBNicholas BrandonChief Scientific Officer
- MKMatthew K. FustIndependent Director
- KMKristina M. BurowIndependent Director
- AHAlaa HalawaIndependent Director
